Buck, your POV sure makes sense to to me.

If an epigenetic molecule has a positive (from a medical perspective) interaction with a specific statin (as per the 5 point MACE results) then a non scientist like me would assume that the population of rousavastatin patients could benefit significantly from a positive interaction with apabetelone. At this point we do not know the 3 point results for either.

I'm beginning to wonder. Is epigenetics a "soft" science. By that I am simply asking the question if molecules like apabetalone are like aspirin (which I think might be great?) or might it have a hard hit (where I am saying it has fairly immediate and observable results?).

I really have no perspective on this after being involved as a shareholder for over 10 years and studying so many great posts and perspectives. 

Cheers, GLTA

TOINV